Cargando…
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
The role of HER4 in breast cancer is controversial and its role in relation to trastuzumab resistance remains unclear. We showed that trastuzumab treatment and its acquired resistance induced HER4 upregulation, cleavage and nuclear translocation. However, knockdown of HER4 by specific siRNAs increas...
Autores principales: | Nafi, Siti Norasikin Mohd, Generali, Daniele, Kramer-Marek, Gabriela, Gijsen, Merel, Strina, Carla, Cappelletti, Mariarosa, Andreis, Daniele, Haider, Syed, Li, Ji-Liang, Bridges, Esther, Capala, Jacek, Ioannis, Roxanis, Harris, Adrian L, Kong, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171603/ https://www.ncbi.nlm.nih.gov/pubmed/25153719 |
Ejemplares similares
-
ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2014) -
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013) -
A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer
por: Mohamed, Malisalaora, et al.
Publicado: (2021) -
Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer
por: Gijsen, M, et al.
Publicado: (2010) -
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)